ArticleOpen medicine (Warsaw, Poland)2026
Frequencies of PD-1 and LAG-3 positive T cells in asthmatic children and their relationship with inflammatory cytokines.
Article in Open medicine (Warsaw, Poland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to investigate the expression of programmed cell death protein 1 (PD-1) and lymphocyte-activation gene 3 (LAG-3) on CD4 Methods: A prospective observational study was conducted involving 112 asthmatic children aged 5-15 years and 100 healthy controls. Peripheral blood mononuclear cells (PBMCs) were isolated, and flow cytometry was used to analyze the frequencies of PD-1 Results: Asthmatic children, particularly those with moderate-to-severe disease, exhibited significantly higher frequencies of PD-1 Conclusions: The elevated frequencies of PD-1 and LAG-3 on T cells in asthmatic children, particularly in those with moderate-to-severe disease, suggested that these immune checkpoint molecules play a critical role in asthma pathogenesis and severity. These findings highlighted the potential of PD-1 and LAG-3 as biomarkers for asthma severity and therapeutic targets, offering new avenues for immune modulation in pediatric asthma management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.